Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours

2005 ◽  
Vol 19 (4) ◽  
pp. 585-594 ◽  
Author(s):  
Dermot O'Toole ◽  
Philippe Ruszniewski
Keyword(s):  
Liver Metastases ◽  
Endocrine Tumours ◽  
Ablative Therapies

Ablative therapies for liver metastases of digestive endocrine tumours.

2003 ◽  
pp. 463-468 ◽  
Author(s):  
D O'Toole ◽  
F Maire ◽  
P Ruszniewski
Keyword(s):  
Liver Metastases ◽  
Somatostatin Analogs ◽  
Hepatic Metastases ◽  
Vascular Occlusion ◽  
Treatment Method ◽  
Vascular Tumors ◽  
Endocrine Tumors ◽  
Hepatic Ischemia ◽  
Ablative Therapies

Hepatic metastases are frequently encountered in patients with digestive endocrine tumors and their presence plays an important role in quality of life and overall prognosis. Surgery is the treatment method of choice for hepatic metastases but this is frequently impossible due to the extent of disease. Systemic chemotherapy is offered to patients with diffuse and/or progressive liver metastases but results are disappointing especially in patients with metastases of midgut origin. In the latter patients with carcinoid syndrome, somatostatin analogs are frequently initially effective but their efficacy wanes due to disease progression and development of tachyphylaxis. Other therapeutic options in the treatment of hepatic metastases are locoregional strategies where vascular occlusion induces ischemia in these highly vascular tumors using either surgical or radiological techniques. Available methods include surgical ligation of the hepatic artery, transient hepatic ischemia or sequential hepatic arterialization. Trans-catheter arterial chemoembolization has proven effective in terms of long palliation and objective tumor responses. Other treatments aimed at regional destruction either alone or in combination with surgery include radiofrequency ablation and cryotherapy. The latter are usually important adjuncts to surgery and are usually reserved for limited disease.

scholarly journals Thermal Ablation of Metastatic Colon Cancer to the Liver

2019 ◽  
Vol 36 (04) ◽  
pp. 310-318 ◽  
Author(s):  
Juan C. Camacho ◽  
Elena N. Petre ◽  
Constantinos T. Sofocleous
Keyword(s):  
Liver Metastases ◽  
Thermal Ablation ◽  
Interventional Oncology ◽  
Percutaneous Ablation ◽  
Western World ◽  
Metastatic Colon Cancer ◽  
Term Survival ◽  
Ablative Therapies

AbstractColorectal cancer (CRC) is responsible for approximately 10% of cancer-related deaths in the Western world. Liver metastases are frequently seen at the time of diagnosis and throughout the course of the disease. Surgical resection is often considered as it provides long-term survival; however, few patients are candidates for resection. Percutaneous ablative therapies are also used in the management of this patient population. Different thermal ablation (TA) technologies are available including radiofrequency ablation, microwave ablation (MWA), laser, and cryoablation. There is growing evidence about the role of interventional oncology and image-guided percutaneous ablation in the management of metastatic colorectal liver disease. This article aims to outline the technical considerations, outcomes, and rational of TA in the management of patients with CRC liver metastases, focusing on the emerging role of MWA.

W1405 Heterogeneity in the Expression of Prognostic Markers in Liver Metastases of Pancreatic Endocrine Tumours

2008 ◽  
Vol 134 (4) ◽  
pp. A-697-A-698
Author(s):  
Anne Couvelard ◽  
Lydia Deschamps ◽  
Philippe Ravaud ◽  
Gabriel Baron ◽  
Alain Sauvanet ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Prognostic Markers ◽  
Endocrine Tumours ◽  
Pancreatic Endocrine Tumours

Ablative therapies for colorectal liver metastases: a systematic review

2011 ◽  
Vol 13 (9) ◽  
pp. e252-e265 ◽  
Author(s):  
S. Pathak ◽  
R. Jones ◽  
J. M. F. Tang ◽  
C. Parmar ◽  
S. Fenwick ◽  
...  
Keyword(s):  
Systematic Review ◽  
Liver Metastases ◽  
Colorectal Liver Metastases ◽  
Ablative Therapies

Role of Chemoembolization in Synchronous Liver Metastases from Pancreatic Endocrine Tumours

1999 ◽  
Vol 16 (1) ◽  
pp. 32-38 ◽  
Author(s):  
M. Falconi ◽  
C. Bassi ◽  
A. Bonora ◽  
N. Sartori ◽  
C. Procacci ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Endocrine Tumours ◽  
Synchronous Liver Metastases ◽  
Pancreatic Endocrine Tumours

scholarly journals Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours

2006 ◽  
Vol 96 (1) ◽  
pp. 49-55 ◽  
Author(s):  
F Marrache ◽  
M P Vullierme ◽  
C Roy ◽  
Y El Assoued ◽  
A Couvelard ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Liver Metastases ◽  
Body Mass ◽  
Arterial Phase ◽  
Endocrine Tumours ◽  
Predictors Of Response

Systematic review and meta-analysis of local ablative therapies for resectable colorectal liver metastases

2020 ◽  
Vol 46 (5) ◽  
pp. 772-781 ◽  
Author(s):  
Marcello Di Martino ◽  
Gianluca Rompianesi ◽  
Ismael Mora-Guzmán ◽  
Elena Martín-Pérez ◽  
Roberto Montalti ◽  
...  
Keyword(s):  
Systematic Review ◽  
Liver Metastases ◽  
Colorectal Liver Metastases ◽  
Meta Analysis ◽  
Ablative Therapies

scholarly journals Prognostic factors in patients with endocrine tumours of the duodenopancreatic area

Gut ◽  
1998 ◽  
Vol 43 (3) ◽  
pp. 422-427 ◽  
Author(s):  
I Madeira ◽  
B Terris ◽  
M Voss ◽  
A Denys ◽  
A Sauvanet ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Cell Differentiation ◽  
Liver Metastases ◽  
Tumour Size ◽  
Primary Tumour ◽  
Complete Resection ◽  
Endocrine Tumours ◽  
Tumoral Cell ◽  
Node Metastases ◽  
Extrahepatic Metastases

Background—The development of endocrine tumours of the duodenopancreatic area (ETDP) is thought to be slow, but their natural history is not well known. The aim of this study was to determine the factors that influence survival of patients with ETDP.Patients/Methods—Eighty two patients with ETDP (44 non-functioning tumours, 23 gastrinomas, seven calcitonin-secreting tumours, four glucagonomas, three insulinomas, one somatostatinoma) followed from October 1991 to June 1997 were included in the study. The following factors were investigated: primary tumour size, hormonal clinical syndrome, liver metastases, lymph node metastases, extranodular/extrahepatic metastases, progression of liver metastases, local invasion, complete resection of the primary tumour, and degree of tumoral differentiation. The prognostic significance of these factors was investigated by uni- and multi-variate analysis.Results—Twenty eight patients (34%) died within a median of 17 months (range 1–110) from diagnosis. Liver metastases (p = 0.001), lymph node metastases (p = 0.001), progression of liver metastases (p<0.00001), lack of complete resection of the primary tumour (p = 0.001), extranodular/extrahepatic metastases (p = 0.001), local invasion (p = 0.001), primary tumour size ⩾3 cm (p = 0.001), non-functioning tumours (p = 0.02), and poor tumoral differentiation (p = 0.006) were associated with an unfavourable outcome by univariate analysis. Multivariate analysis identified only liver metastases (risk ratio (RR) = 8.3; p<0.0001), poor tumoral cell differentiation (RR = 8.1; p = 0.0001), and lack of complete resection of the primary tumour (RR = 4.8; p = 0.0007) as independent risk factors. Five year survival rates were 40 and 100% in patients with and without liver metastases, 85 and 42% in patients with and without complete resection of primary tumour, and 17 and 71% in patients with poor and good tumour cell differentiation respectively.Conclusion—Liver metastases are a major prognostic factor in patients with ETDP. Progression of liver metastases is also an important factor which must be taken into account when deciding on the therapeutic approach. The only other independent prognostic factors are tumoral cell differentiation and complete resection of the primary tumour.

Sign in / Sign up

Export Citation Format

Share Document